JPRN-UMIN000009746已完成2 期
The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer - The Phase II Study of Combination Cell-based Immunotherapy in Patients with Treatment-refractory Lung Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency ) 2) Active infections 3) Active simultaneous cancer 4)Massive pleural or pericardial effusion 5) Concurrent treatment with steroids or immunosuppressing agent 6) Other conditions not suitable for this study
研究者
相似试验
尚未招募
2 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03ANL-OMON56282Merck Sharp & Dohme (MSD)5
招募中
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Sub study 03BMedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864Renal cell carcinomaCTIS2023-506839-15-00Merck Sharp & Dohme LLC244
招募中
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Sub study 03AMedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864Renal cell carcinomaCTIS2023-506838-68-00Merck Sharp & Dohme LLC267
进行中（未招募）
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03BRenal Cell CarcinomaMedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864EUCTR2019-003610-13-HUMerck Sharp & Dohme LLC370
进行中（未招募）
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03ARenal Cell CarcinomaEUCTR2019-003609-84-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc430